The Duckhorn Portfolio Confirms Guidance for 2024

The Duckhorn Portfolio Confirms Guidance for 2024

By Karen Roman The Duckhorn Portfolio, Inc. (NYSE: NAPA) reported net sales increased 1.4% year over year to reach $92.5 million in its Q3 2024 results. Adjusted EBITDA grew 5.3% to $37.7 million year over year and adjusted EBITDA margin...

MOBILion Shows Off MOBIE System at ASMS 2024

MOBILion Shows Off MOBIE System at ASMS 2024

By Karen Roman MOBILion Systems announced it is presenting the latest features of its mass spectrometry platform, MOBIE EyeOn 2.3, at the 72nd American Society for Mass Spectrometry (ASMS) Conference in California. The latest software introduces new capabilities and streamlines...

Sparrow Pharmaceuticals Announces Cushing’s Syndrome Treatment Results

Sparrow Pharmaceuticals Announces Cushing’s Syndrome Treatment Results

By Daniella Parra Sparrow Pharmaceuticals said its HSD-1 inhibitor, clofutriben (SPI-62), normalized urine free cortisol in over 60% of patients with endogenous Cushing’s syndrome without significantly lowering serum cortisol, minimizing the risk of adrenal insufficiency. Traditional EnCS treatments require careful...

Dar Charity Foundation Lights the Flame of Learning

Dar Charity Foundation Lights the Flame of Learning

New School photos courtesy of Dar Charity Foundation Furthering Nikita Mishin’s Educational Vision By Exec Edge Editorial Staff Education is one of the most powerful tools for social change and human development. But in many parts of the world, access...

Kohl’s First Quarter Regular Price Sales Climb

Kohl’s First Quarter Regular Price Sales Climb

By Daniella Parra Kohl’s Corp. (NYSE:KSS) said regular price sales increased 2.4% in the first quarter. Net sales decreased 5.3% year-over-year to $3,178 million in the quarter and the company had a loss of 24 cents per share against earnings...

Movado Group Maintains Guidance for FY2025

Movado Group Maintains Guidance for FY2025

By Karen Roman Movado Group, Inc. (NYSE: MOV) maintained guidance for fiscal 2025 with net sales between $700 million and $710 million, gross profit margin around 55% and operating income between $32 million to $35 million. Net sales decreased 5.7%...

Waldencast Net Revenue Climbs 21% in First Quarter

Waldencast Net Revenue Climbs 21% in First Quarter

By Karen Roman Waldencast plc (Nasdaq: WALD), a multi-brand beauty and wellness company, said comparable net revenue increased 21% year over year to $68.3 million in the first quarter. Adjusted gross profit grew 32.9% reaching $52.1 million in the quarter...

Creyon Bio Using AI to Treat Rare Neurological Diseases

Creyon Bio Using AI to Treat Rare Neurological Diseases

By Daniella Parra Creyon Bio, Inc. said it is using AI to engineer treatments for rare and common diseases. The platform’s ability to predict and mitigate safety concerns signifies a promising advancement as they customized a treatment within a year,...

Input your search keywords and press Enter.